Trichomonas vaginalis carbonic anhydrase

Research output: Chapter in Book/Report/Conference proceedingChapterScientificpeer-review

Abstract

Trichomoniasis is the most common sexually transmitted infection. It is caused by the parasite Trichomonas vaginalis. Nitroimidazoles, particularly metronidazole and tinidazole, have been the main treatment options for decades. They still remain the standard treatment, and resistance to them is relatively rare. However, cases of resistance do occur, and the side effects can be significant. This highlights the urgent need for new drugs with different mechanisms of action. Promisingly, several innovative leads have emerged. Interesting drug targets in T. vaginalis include two β-carbonic anhydrases, which have been recently described. These enzymes have been characterized in terms of their structural and kinetic properties, and potential inhibitors have been identified. This new knowledge on β-carbonic anhydrases offers hope for the development of novel antitrichomonal agents to effectively combat this parasitic disease in the future.

Original languageEnglish
Title of host publicationThe Enzymes
Subtitle of host publicationVolume 57: Fungal and Protozoan Carbonic Anhydrases
PublisherAcademic Press
Pages207-218
ISBN (Print)978-0-443-31394-3
DOIs
Publication statusPublished - 2025
Publication typeA3 Book chapter

Publication series

NameEnzymes
PublisherElsevier BV
Volume57
ISSN (Print)1874-6047

Keywords

  • Sulfonamides
  • Trichomonas vaginalis
  • TvaCA1
  • TvaCA2
  • β-carbonic anhydrases

Publication forum classification

  • Publication forum level 2

ASJC Scopus subject areas

  • Biotechnology
  • Biophysics
  • Biochemistry
  • Molecular Biology

Fingerprint

Dive into the research topics of 'Trichomonas vaginalis carbonic anhydrase'. Together they form a unique fingerprint.

Cite this